Organoids are a three-dimensional (3D) cell culture system that has proven to be an excellent alternative to animal models in preclinical studies.

As a relatively "young" technology, iPSC technology shows bright prospects.

Our country should also follow international practice and promote "autologous stem cells as a third type of medical technology management."

In the cutting-edge exploration of diabetes treatment, stem cell therapy is showing unprecedented potential and prospects.

This article provides an overview of cell culture media, suspension models, and monitoring technologies that can maintain the quality and pluripotency of iPSC during induction, expansion, and production.

With the continuous development of technology, stem cells will surely trigger a medical revolution and become the third treatment method after drugs and surgery.

As a new pharmaceutical product, stem cell drugs are expected to make huge contributions to the pharmaceutical and medical industries in the near future.

New research demonstrates the great promise of iMSCs and iMSCs-EVs as alternative sources of MSC-derived therapies because of their powerful immunomodulatory and regenerative properties.